Pharmaceutical Safety Review • Moderate Interaction Classification
Triglyceride Omega-3 vs Ethyl Ester vs Krill Oil Prescription Drug Interactions & CYP450 Profile
Systematic analysis of cytochrome P450 enzyme metabolism, renal clearance competition, and clinical contraindications.
Absolute Clinical Contraindications
- Concurrent high-dose antithrombotic or anticoagulant therapy without INR monitoring
- Fish or shellfish allergy (for krill)
- Upcoming scheduled major surgery
Reported Clinical Adverse Events
- Fishy burps or reflux (sign of high oxidation or EE formulation)
- Mild loose stools at >4g doses
- Increased bleeding time
Hepatic Cytochrome P450 (CYP) & Transporter Pathways
Compounds that modulate CYP3A4, CYP2D6, or P-glycoprotein (P-gp) can alter the bioavailability of concurrent medications including statins, anticoagulants, immunosuppressants, and blood pressure therapies:
- CYP3A4 Substrate / Inhibitor: Potential competition with oral medications metabolized through hepatic CYP3A4 pathways.
- Gastrointestinal Transit Modulation: GLP-1 receptor agonists and delayed-release botanicals slow gastric emptying, which may delay Tmax for orally administered therapeutics.
- Pharmacokinetic Half-Life Clearance: Systemic clearance requires approximately 5 elimination half-lives (RBC membrane incorporation half-life: 4 - 8 weeks).